Study of combination chemotherapy for Wilms tumor in children
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are 30 years old or younger when joining the study.
- Diagnosis fits one of these: newly diagnosed stages 2–4 diffuse anaplastic Wilms tumor, or favorable histology Wilms tumor that is in first relapse after full remission.
- Newly diagnosed diffuse anaplastic cases must be enrolled on a separate screening study soon after the tumor surgery/biopsy that first confirmed the diagnosis.
- You must have proof of the tumor type from central review, and for relapse cases there must be a favorable-histology pathology report available to upload.
- You must be well enough to tolerate treatment (performance score 0–2) and expected to live at least 8 weeks.
- Recent blood tests must be adequate (including minimum neutrophils, platelets, and hemoglobin), and heart/liver/kidney measurements must meet study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
This study tailors treatment for children with Wilms tumor based on specific tumor features and risk factors. The goal is to give the right amount of therapy to each patient to minimize side effects while maintaining high cure rates.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
This Phase 2 study tests whether sirolimus combined with low-dose (“metronomic”) chemotherapy can help children and young adults with certain high-risk solid tumors stay in remission or reduce recurrence risk. It is designed for people whose cancer has responded well to initial treatment, with only minimal or no visible disease on scans.
This Phase 3 study tests a chemotherapy plan for children and teens with newly diagnosed, very low-risk or low-risk rhabdomyosarcoma that does not have certain gene fusions (FOXO1 fusion negative). The goal is to see if this treatment can work well while limiting side effects by matching therapy to early-stage risk.
Hear when a new Anaplastic Kidney Wilms Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.